🌟 Avapag 20 mg (Avapritinib) – Everest Pharma

Avapag 20 mg contains Avapritinib, a precision-targeted tyrosine kinase inhibitor (TKI) designed to selectively inhibit mutant forms of KIT and PDGFRA proteins that drive tumor growth. It represents a significant advancement in the treatment of gastrointestinal stromal tumors (GIST) with specific mutations that are resistant to other therapies.

💊 Composition

Each film-coated tablet contains:
👉 Avapritinib 20 mg

⚡ Indications

Avapag 20 mg is indicated for the treatment of:

• Adults with unresectable or metastatic gastrointestinal stromal tumors (GIST)

• Specifically for patients whose tumors harbor a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, which are resistant to standard TKIs

📌 Key Features

✅ Highly selective inhibitor of PDGFRA exon 18 mutant and KIT mutant kinases
✅ Targeted therapy for resistant GIST
✅ Oral once-daily administration for patient convenience
✅ Developed by Everest Pharmaceuticals Ltd., dedicated to accessible, high-quality oncology solutions

🕒 Dosage & Administration

• Recommended dose: 300 mg once daily (using combinations of tablet strengths as prescribed by a healthcare provider)

• Tablets should be swallowed whole on an empty stomach (at least 1 hour before and 2 hours after a meal)

🏭 Manufacturer

Everest Pharmaceuticals Ltd.
A trusted manufacturer of affordable, high-quality targeted cancer therapies for global oncology care.

📌 Category

➡️ Oncology / Anti-cancer Medicine
➡️ Targeted Therapy / Precision Medicine
➡️ Tyrosine Kinase Inhibitor (TKI)

🧬 Therapeutic Class

• Selective PDGFRA/KIT inhibitor

• Molecular targeted agent for solid tumors (GIST)

🚀 Why Choose Avapag?

Avapag 20 mg (Avapritinib) offers hope for patients with rare, hard-to-treat gastrointestinal stromal tumors by delivering precision therapy against mutations that evade standard treatments. It exemplifies Everest Pharma’s commitment to innovation and patient-centered care.